Skip to content
Roboearth – Lifestyle
Author:
R1 Therapeutics
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
March 17, 2026